Filing summary
Identity discrepancy: The request identifies Crescent Biopharma, Inc., but the supplied Form 10-Q is for GlycoMimetics, Inc. (Nasdaq: GLYC). The summary below reflects the filing text provided, for the quarter ended September 30, 2023.
Business context and reporting period
GlycoMimetics is a clinical-stage biotechnology company developing glycomimetic drug candidates for cancer and inflammatory diseases. It has no approved products, has not generated product-sales revenue, and reports continuing operating losses. The unaudited filing covers the three and nine months ended September 30, 2023, with comparisons to the same 2022 periods.
Financial performance and position
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $75,000 |
| Research and development expense | $5.29 million | $4.92 million | $14.78 million | $22.50 million |
| General and administrative expense | $4.52 million | $3.84 million | $14.90 million | $14.36 million |
| Net loss | $9.20 million | $8.52 million | $27.82 million | $36.44 million |
| Net loss per share, basic and diluted | $0.14 | $0.16 | $0.44 | $0.70 |
Interest income was $0.61 million in Q3 and $1.86 million for the first nine months of 2023, up from $0.24 million and $0.34 million, respectively, in 2022; management attributed the increases to higher interest rates. No product revenue or material collaboration revenue was reported in 2023. The filing provides no meaningful operating margin comparison because revenue was nil.
At September 30, 2023, cash and cash equivalents were $49.41 million, total assets $53.20 million, total liabilities $6.65 million, and stockholders’ equity $46.55 million. The accumulated deficit was $447.41 million. The filing reports no borrowings; lease liabilities were approximately $1.01 million, including current and long-term portions. Nine-month operating cash use was $27.26 million, investing cash use was $0.02 million, and financing cash inflow was $28.82 million, primarily from stock sales. Cash increased by $1.54 million from year-end 2022.
Material changes versus prior comparable periods
- Q3 net loss increased by $0.68 million year over year as total expenses rose 12%; R&D increased 7% and G&A increased 18%.
- Nine-month net loss narrowed by $8.62 million, with total expenses down 19%. R&D expense fell 34%, principally reflecting lower uproleselan clinical and manufacturing costs after trial enrollment ended and reduced personnel costs following a 2022 workforce reduction.
- G&A increased 4% over nine months, with management citing personnel and professional fees related in part to potential regulatory submission and commercialization preparations.
- The company raised $28.7 million net through its at-the-market facility in Q1 2023 by issuing 9.82 million shares; approximately $66.0 million remained available under the facility at September 30. No sales occurred after March 31, 2023.
Outlook, commentary, and risks
- Management expected existing cash to fund operations into late Q4 2024, excluding potential business-development payments and additional financing. The filing also states that cash at September 30 was expected to cover at least 12 months from issuance. Both estimates depend on assumptions and clinical-trial spending and timing.
- Topline results from the pivotal Phase 3 uproleselan trial in relapsed/refractory AML were expected by the end of Q2 2024 after an FDA-cleared protocol amendment enabling a time-based overall-survival analysis if the planned event count had not been reached. The IDMC had recommended in February 2023 that the trial continue to its planned final analysis.
- GMI-1687’s Phase 1a healthy-volunteer trial began enrollment in August 2023; initial results were expected by the end of Q1 2024. The company also described ongoing pediatric and NCI-sponsored uproleselan studies.
- The company expects continuing losses and may need additional equity, debt, collaboration, or other financing. Additional capital may be unavailable or dilutive; failure to obtain funding could delay, limit, or terminate development or commercialization efforts. No profitability or positive operating cash flow is assured.
- Development, regulatory approval, manufacturing, commercialization, intellectual-property protection, reimbursement, and clinical-trial outcomes remain significant uncertainties. The company reported no material legal proceedings and no material change to the risk factors in its 2022 Form 10-K.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is GlycoMimetics, Inc., not Crescent Biopharma, Inc.
- Check subsequent disclosures for uproleselan Phase 3 topline timing, results, and any regulatory filing plans.
- Monitor GMI-1687 Phase 1a results and progress in the other clinical programs.
- Track cash burn, the stated late-Q4-2024 runway estimate, and any financing or use of the remaining ATM capacity, including potential dilution.
- Review the full risk-factor disclosures and subsequent filings for changes to clinical, regulatory, funding, or collaboration developments.